Sir,

Cervical cancer is the most common type worldwide. Human papillomavirus (HPV) is an important etiology of this cancer.\[1\] At present, the prevention of this cancer is possible since cervical cancer vaccine is available.\[2\] For vaccination, there is still an argument on the effective regimen. The topic that is widely discussed is the selection for two-dose or three-dose regimens for vaccinating the young women who should receive the cervical cancer vaccine.\[2\] Indeed, the two-dose and three-dose cervical cancer vaccination regimens are mentioned in several reports from different settings.\[3-9\] Many reports usually use the immunogenicity for judgment of proper regimen. For example, the study from India noted that the two-dose regimen could induce sufficient immunogenicity.\[6\] Sankaranarayanan et al. studied difference regimens and recommended the two-dose regimen for the Indian situation.\[7-9\] Similar observations are also reported in the study from UK and France.\[4-5\] In another report from the Netherlands, the immunogenicity of vaccine in the two-dose and three-dose regimen is not different.\[3\] Nevertheless, the economical concern is also important in regimen selection.

In this short report, the author compares the two regimens. The cost–utility comparison based on the present epidemiology of HPV in Thailand is done. In analysis, the cost refers to the unit for each regimen reported by referencing tertiary hospitals in Thailand (Vibhavadi hospital, Bangkok) and presented in USD. The utility is referred to the expected adjusted immunogenicity determined in geometric mean titer at 36 months after vaccination as shown in previous validation study and present in mMU/mL,\[10\] The path probability assignment is according to the recent data from epidemiological study on HPV in cervical smear samples in Thailand.\[11\] The primary data of utility quoted from the referenced study\[10\] and derived expected utility after assignment of path probability are shown in Table 1. Then, cost per utility values for two-dose and three-dose regimens are calculated. The final cost–utility analysis result is presented in Table 2. Based on this study, the three-dose regimen has less cost per utility than the two-dose regimen; hence, the three-dose regimen of cervical cancer vaccination should be used in the study setting. In conclusion, the three-dose regimen of cervical cancer vaccination is hereby recommended based on cost–utility analysis. The finding is an important topic and relevant to other settings\[12,13\] including India. For each setting, the comparative cost–utility analysis is recommended.

### Table 1: Path probability and utility according to the type of human papillomavirus

<table>
<thead>
<tr>
<th>HPV type</th>
<th>Path probability%</th>
<th>Two-dose regimen</th>
<th>Three-dose regimen</th>
</tr>
</thead>
<tbody>
<tr>
<td>HPV-16</td>
<td>1.313</td>
<td>15.112</td>
<td>18.473</td>
</tr>
<tr>
<td>HPV-18</td>
<td>0.053</td>
<td>0.055</td>
<td>0.126</td>
</tr>
<tr>
<td>HPV-6</td>
<td>0.131</td>
<td>0.318</td>
<td>0.493</td>
</tr>
<tr>
<td>HPV-11</td>
<td>0.197</td>
<td>0.587</td>
<td>0.796</td>
</tr>
<tr>
<td>Overall</td>
<td>1.694</td>
<td>16.073</td>
<td>19.888</td>
</tr>
</tbody>
</table>

\[a\]The reported utility is referred to the expected adjusted immunogenicity determined in geometric mean titer at 36 months after vaccination as shown in previous validation study and present in mMU/mL.\[10\] 
\[b\]Expected utility after assignment of path probability is calculated for each HPV type by multiplying the path probability with corresponding reported utility.\[c\]The path probability assignment is according to the recent data from epidemiology of HPV in cervical smear sample in Thailand.\[11\] HPV – Human papillomavirus.

### Table 2: Cost-utility analysis comparing three-dosage cervix cancer vaccination regimen for young women based on the situation in Thailand

<table>
<thead>
<tr>
<th></th>
<th>Two-dose regimen</th>
<th>Three-dose regimen</th>
</tr>
</thead>
<tbody>
<tr>
<td>Overall cost (USD)</td>
<td>154.41</td>
<td>181.49</td>
</tr>
<tr>
<td>Overall utility (mMU/mL)</td>
<td>16.07</td>
<td>19.89</td>
</tr>
<tr>
<td>Cost per utility (USD)</td>
<td>9.61</td>
<td>9.12</td>
</tr>
</tbody>
</table>

The overall cost is referred to the unit for each regimen reported by referencing tertiary hospitals in Thailand (Vibhavadi Hospital, Bangkok) and presented in USD. The overall utility derived from the calculation as presented in Table 1, Cost per utility value is equal to overall cost/overall utility. For example, the cost per utility for two-dose regimen is equal to 181.49/19.89 USD.

### Financial support and sponsorship

Nil.

### Conflicts of interest

There are no conflicts of interest.

Beuy Joob, Viroj Wiwanitkit\[1,2,3\]

Sanitation 1 Medical Academic Center, Bangkok, Thailand, 1 Department of Medical Science, Faculty of Medicine, University of Nis, Nis, Serbia, 2 Department of Community Medicine, Dr. D. Y. Patil University, Pune, Maharashtra, India, 3 Department of Biological Science, Joseph Ayo Babalola University, Ileaji-Arakeji, Osun State, Nigeria.
Address for correspondence:
Dr. Beuy Joob,
Sanitation 1 Medical Academic Center, Bangkok, Thailand.
E-mail: beuyjoob@hotmail.com

References


This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

Access this article online

Quick Response Code:
Website: www.ijmpo.org
DOI: 10.4103/ijmpo.ijmpo_163_17

How to cite this article: Joob B, Wiwanitkit V. 3 Doses versus 2 doses cervical cancer vaccination regimen: Cost–utility analysis based on Tropical Southeast Asian Country, Thailand, Situation. Indian J Med Paediatr Oncol 2019;40:S192-3.

© 2019 Indian Journal of Medical and Paediatric Oncology | Published by Wolters Kluwer / Medknow